These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 8773956)

  • 21. Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model.
    Kimko HC; Reele SS; Holford NH; Peck CC
    Clin Pharmacol Ther; 2000 Nov; 68(5):568-77. PubMed ID: 11103759
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of arteriovenous concentration differences on pharmacodynamic parameter estimates.
    Tuk B; Danhof M; Mandema JW
    J Pharmacokinet Biopharm; 1997 Feb; 25(1):39-62. PubMed ID: 9353693
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is it possible to estimate the parameters of the sigmoid Emax model with truncated data typical of clinical studies?
    Dutta S; Matsumoto Y; Ebling WF
    J Pharm Sci; 1996 Feb; 85(2):232-9. PubMed ID: 8683454
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship between pharmacokinetic half-life and pharmacodynamic half-life in effect-time modeling.
    Keller F; Czock D; Zellner D; Giehl M
    Int J Clin Pharmacol Ther; 1998 Mar; 36(3):168-75. PubMed ID: 9562234
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population Pharmacodynamic Modeling Using the Sigmoid E
    Proost JH; Eleveld DJ; Struys MMRF
    AAPS J; 2020 Dec; 23(1):10. PubMed ID: 33367961
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Bayesian approach for PK/PD modeling with PD data below limit of quantification.
    Zhou H; Hartford A; Tsai K
    J Biopharm Stat; 2012; 22(6):1220-43. PubMed ID: 23075019
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of mixture modeling with count data using NONMEM.
    Frame B; Miller R; Lalonde RL
    J Pharmacokinet Pharmacodyn; 2003 Jun; 30(3):167-83. PubMed ID: 14571690
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population pharmacodynamic parameter estimation from sparse sampling: effect of sigmoidicity on parameter estimates.
    Pai SM; Girgis S; Batra VK; Girgis IG
    AAPS J; 2009 Sep; 11(3):535-40. PubMed ID: 19629711
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Simultaneous versus sequential pharmacokinetic-pharmacodynamic population analysis using an iterative two-stage Bayesian technique.
    Proost JH; Schiere S; Eleveld DJ; Wierda JM
    Biopharm Drug Dispos; 2007 Nov; 28(8):455-73. PubMed ID: 17847121
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Implementing a decision-theoretic design in clinical trials: why and how?
    Palmer CR; Shahumyan H
    Stat Med; 2007 Nov; 26(27):4939-57. PubMed ID: 17582801
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of manual versus ambulatory blood pressure measurements with pharmacokinetic-pharmacodynamic modeling of antihypertensive compounds: application to moxonidine.
    Trocóniz IF; de Alwis DP; Tillmann C; Callies S; Mitchell M; Schaefer HG
    Clin Pharmacol Ther; 2000 Jul; 68(1):18-27. PubMed ID: 10945312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An adaptive confirmatory trial with interim treatment selection: practical experiences and unbalanced randomization.
    Heritier S; Lô SN; Morgan CC
    Stat Med; 2011 Jun; 30(13):1541-54. PubMed ID: 21432887
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of dose-finding designs for narrow-therapeutic-index drugs: concentration-controlled vs. dose-controlled trials.
    Lledó-García R; Hennig S; Karlsson MO
    Clin Pharmacol Ther; 2009 Jul; 86(1):62-9. PubMed ID: 19339964
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biomarker-based Bayesian randomized phase II clinical trial design to identify a sensitive patient subpopulation.
    Morita S; Yamamoto H; Sugitani Y
    Stat Med; 2014 Oct; 33(23):4008-16. PubMed ID: 24820639
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypothesis testing and Bayesian estimation using a sigmoid Emax model applied to sparse dose-response designs.
    Thomas N
    J Biopharm Stat; 2006; 16(5):657-77. PubMed ID: 17037264
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and concentration-effect analysis of intravenous RGD891, a platelet GPIIb/IIIa antagonist, using mixed-effects modeling (NONMEM).
    Zannikos PN; Rohatagi S; Jensen BK; DePhillips SL; Rhodes GR
    J Clin Pharmacol; 2000 Oct; 40(10):1129-40. PubMed ID: 11028252
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Errors associated with metabolic control analysis. Application Of Monte-Carlo simulation of experimental data.
    Ainscow EK; Brand MD
    J Theor Biol; 1998 Sep; 194(2):223-33. PubMed ID: 9778435
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reliability of pharmacodynamic analysis by logistic regression: mixed-effects modeling.
    Lu W; Ramsay JG; Bailey JM
    Anesthesiology; 2003 Dec; 99(6):1255-62. PubMed ID: 14639136
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adaptive designs for dose-finding studies based on sigmoid Emax model.
    Dragalin V; Hsuan F; Padmanabhan SK
    J Biopharm Stat; 2007; 17(6):1051-70. PubMed ID: 18027216
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bayesian adaptive D-optimal design with delayed responses.
    Li J; Fu H
    J Biopharm Stat; 2013 May; 23(3):559-68. PubMed ID: 23611195
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.